DexCom Inc. (DXCM)

Name: DexCom Inc. (DXCM) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: DexCom Inc. (DXCM)

Stock Card

$82.29

$2.36 (2.95%)

As on 30-Oct-2026 16:00EST

Market cap

$30,690 Mln

Revenue (TTM)

$5,104 Mln

P/E Ratio

32.4

P/B Ratio

12.1

Div. Yield

0 %

DexCom (DXCM) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 79.79 High: 85.25

52 Week Range

Low: 54.11 High: 92.59

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

0.4 %
ROCE

19 %
Industry P/E

47.17
EV/EBITDA

18
Debt to Equity

0.5
Book Value

$6.8
EPS

$2.5
Face value

--
Shares outstanding

372,950,922

10 Years Aggregate

CFO

$2,994.60 Mln

EBITDA

$1,895.00 Mln

Net Profit

$1,309.20 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
DexCom (DXCM)	24.0	-5.0	9.5	20.7	-2.7	-12.0	15.7
BSE Sensex^*	-11.1	4.7	-3.6	-10.3	5.8	4.6	10.4
S&P 100	8.1	-2.4	3.4	7.4	24.4	12.0	14.7

As on 30-Oct-2026 | *As on 02-Nov-2026

Company	2025	2024	2023	2022	2021	2020	2019
DexCom (DXCM)	-14.7	-37.1	9.6	-15.6	45.2	69.0	82.6
S&P 100	18.7	29.0	30.8	-22.1	27.6	19.3	29.5
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
DexCom (DXCM)	82.3	30,690.1	5,104.4	991.0	25.0	36.1	32.4	12.1
Abbott Laboratories (ABT)	106.2	180,946.2	48,229.0	4,701.0	11.8	18.1	38.9	3.5
Boston Scientific Corp (BSX)	42.0	61,867.6	21,069.0	3,490.0	15.2	27	18	2.5
Danaher (DHR)	232.2	166,593.6	25,608.0	4,331.0	20.2	8.1	39.2	3.1
Illumina (ILMN)	236.0	35,634.5	4,539.0	895.0	24.4	30.8	44	11.3
Intuitive Surgical (ISRG)	432.0	152,619.7	11,578.0	2,957.2	33.8	17.6	54.3	9.9
ResMed (RMD)	229.9	35,557.8	5,732.7	1,593.2	35.1	25.6	24.2	5.3
Stryker (SYK)	291.9	119,578.9	26,300.0	3,623.0	20.6	15.6	32.3	4.9
Thermo Fisher Scientific (TMO)	697.0	262,217.4	47,351.0	7,083.0	13.6	13.2	37.4	4.8
West Pharmaceutical Services (WST)	412.6	29,323.5	3,396.7	638.9	23.1	21.4	53.4	9.5

Shareholding Pattern

View Details

About DexCom (DXCM)

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company... offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California. Read more

Executive Chairman, CEO & President

Mr. Kevin Ronald Sayer
Executive Chairman, CEO & President

Mr. Kevin Ronald Sayer
Headquarters

San Diego, CA
Website

https://www.dexcom.com

FAQs for DexCom (DXCM)

What is the current share price of DexCom Inc (DXCM) Today?

The share price of DexCom Inc (DXCM) is $82.29 (NASDAQ) as of 30-Oct-2026 16:00 EST. DexCom Inc (DXCM) has given a return of -2.68% in the last 3 years.

What is the current PB & PE ratio of DexCom Inc (DXCM)?

The P/E ratio of DexCom Inc (DXCM) is 32.40 times as on 30-Oct-2026, a 31 discount to its peers’ median range of 47.17 times.
The P/B ratio of DexCom Inc (DXCM) is 12.11 times as on 30-Oct-2026, a 172 premium to its peers’ median range of 4.45 times.

PE & PB ratio at the end of financial year.